Prevencio Announces Presentation of AI-Powered HART PAD Blood Test Data at European Society of Cardiology Congress

Company’s cardiovascular blood tests developed from scalable, AI-driven HART diagnostics platform

KIRKLAND, WA, UNITED STATES, August 25, 2026 /EINPresswire.com/ — Prevencio, Inc., a leader in AI-powered multiprotein blood diagnostics, today announced that data evaluating its HART PAD blood test for peripheral artery disease will be presented at the 2026 European Society of Cardiology (ESC) Congress in Munich, Germany, on August 31, 2026. This year’s ESC Congress features a Spotlight on Artificial Intelligence, highlighting how Artificial Intelligence (AI) is advancing precision, speed, and safety in patient care.

HART PAD is an AI-powered, multiprotein blood test designed to aid in the detection of obstructive peripheral artery disease (PAD), a common but frequently underdiagnosed cardiovascular condition. Earlier identification of PAD may enable more timely clinical management and help reduce the risk of heart attack, stroke, limb amputation, and cardiovascular death.

James L. Januzzi, MD, Chief Scientific Officer of the Baim Institute for Clinical Research and Professor of Medicine at Harvard Medical School, stated, “Although current noninvasive approaches are available to assess presence and severity of PAD, these tools have important limitations, including variable accuracy, limited accessibility, high cost, and, in some cases, intravenous contrast and ionizing radiation. An accurate, AI-powered blood test such as HART PAD has the potential to help clinicians identify disease earlier, improve risk stratification, and guide more appropriate diagnostic evaluation and preventive treatment.”

The Company recently announced that the American Medical Association (AMA) issued a proprietary billing code for HART PAD, an important step in facilitating insurance billing and reimbursement.

Rhonda Rhyne, Prevencio’s CEO and Chief Translational Officer, added, “Prevencio is transforming healthcare through accessible, clinically validated blood tests powered by AI. Our initial commercial focus in cardiovascular disease demonstrates the HART platform’s potential to deliver strong clinical performance while supporting reimbursement and clinical adoption. Because the HART platform is not limited to a single disease, it also provides a scalable foundation for developing a pipeline of innovative, reimbursable diagnostic tests across multiple disease areas and therapeutic indications, creating substantial long-term strategic value.”

Prevencio’s HART platform supports diagnostic tests across multiple cardiovascular conditions, backed by proprietary billing codes, growing commercial adoption, expanding clinical evidence, and increasing payer acceptance.

Corporate Highlights
• Proprietary AMA CPT billing reimbursement codes support Prevencio’s expanding HART portfolio.
• FDA Breakthrough Device Designation for HART CADhs.
• Commercial-stage with Medicare, Medicare Advantage and select commercial reimbursement.
• Growing commercial adoption through expanding laboratory and health system partnerships.
• Proprietary, scalable HART AI-driven diagnostics platform.
• More than 35 peer-reviewed publications and scientific presentations supporting the HART platform.
• Growing global intellectual property portfolio protecting AI algorithms and multiprotein diagnostics.
• Positioning to become a leading precision diagnostics company with significant long-term strategic value.

About Prevencio, Inc.
Prevencio is transforming medicine through AI-powered blood diagnostics that enable earlier, more accurate, and more accessible detection and risk assessment. The Company’s HART platform is disease-agnostic and our first commercial franchise in cardiovascular and cardiometabolic medicine includes HART CADhs, HART CVE, HART PAD, HART KD, HART AS, and HART AKI. Prevencio is committed to improving patient outcomes while reducing unnecessary procedures and healthcare costs through precision diagnostics. Learn more at www.prevenciomed.com.

Forward-Looking Statements
Except for historical and factual information contained herein, this press release contains forward-looking statements, including statements regarding commercialization, reimbursement, launch timing, market opportunity, and future business performance. Actual results may differ materially due to various risks and uncertainties. Prevencio undertakes no obligation to update these statements.

Ella Jane Williams
Prevencio, Inc.
+1 425-576-1200
email us here

Media gallery